---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-23-000064"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2023-10-05T23:59:59+00:00"
generated_at: "2026-06-10T04:26:12.755752+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics COO Nicole Lambert to step down Oct 31; remains consultant through Mar 2024

## Summary
- COO Nicole Lambert will depart as of Oct 31, 2023; will provide consulting services through Mar 31, 2024.
- Lambert receives weekly consulting fee of $4,951.92 and continued equity vesting during consulting period.
- Outstanding RSUs scheduled to vest within one year post-Separation Date will accelerate at Mar 31, 2024.
- Company reaffirmed FY2023 revenue and non-GAAP guidance previously provided on Sep 19 investor day.
- Departure not due to any disagreement with company's operations, policies, or procedures.

## SEC filing metadata
- accession: 0000899923-23-000064
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2023-10-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992323000064/0000899923-23-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992323000064/mygn-20231004.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-23-000064
- JSON: https://secwatch.observer/filing/0000899923-23-000064.json
- Plain text: https://secwatch.observer/filing/0000899923-23-000064.txt

## Key facts
- Executive change
  Nicole Lambert departed as Chief Operating Officer at MYRIAD GENETICS INC.
  - Action: stepped down
  - Role: Chief Operating Officer
  source text: On October 4, 2023, Nicole Lambert, Chief Operating Officer of Myriad Genetics, Inc. (the “Company”) and the Company mutually reached an agreement that Ms. Lambert would step down from such position, effective October 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/899923/000089992323000064/0000899923-23-000064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.